Cardio Diagnostics Brings Molecular Precision to CHD Detection

Coronary heart disease (CHD) remains the leading cause of death in the United States, yet traditional risk assessment tools are failing to catch many cases. According to Cardio Diagnostics Holdings (NASDAQ: CDIO), approximately 50% of individuals with CHD do not have traditional risk factors, and conventional risk calculators have an average sensitivity of only 39%. This means that a significant number of people who appear healthy are actually at risk for preventable cardiac events like heart attacks. For decades, doctors have relied on a checklist of factors such as cholesterol, blood pressure, and smoking history, but these were never designed to capture the full biological picture of heart disease development.

Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics, examining how genes are expressed and regulated at the molecular level. These tests aim to provide a more precise assessment of CHD risk, potentially identifying individuals who would otherwise be missed by standard methods. The company's approach represents a shift toward molecular precision in cardiovascular diagnostics, addressing what has been described as a blind spot in CHD detection. By focusing on the underlying biology rather than just surface-level risk factors, these tests could help prevent many of the preventable deaths caused by heart disease.

For more details, you can Read More>>. The latest news and updates about CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. This news is brought to you by BioMedWire (BMW), a platform focused on the BioTech, BioMed, and Life Sciences sectors, and part of the Dynamic Brand Portfolio @ IBN.